Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 311-322

  Moyret Lalle, Caroline ^a   Ruiz, Emmanuelle ^a   Puisieux, Alain ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Breast cancer; Dicer; Embryonic transcription factors; Epithelial to mesenchymal transition; Feedback loop; MicroRNAs

Indexed keywords

EID: 84920783923     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.311     Document Type: Review

References (82)

1. Wang Y, Dong J, Li D, Lai L, Siwko S, Li Y, Liu M. Lgr4 regulates mammary gland development and stem cell activity through the pluripotency transcription factor Sox2. Stem Cells 2013; 31: 1921-1931 [PMID: 23712846 DOI: 10.1002/stem.1438]
2. Zvelebil M, Oliemuller E, Gao Q, Wansbury O, Mackay A, Kendrick H, Smalley MJ, Reis-Filho JS, Howard BA. Embryonic mammary signature subsets are activated in Brca1-/-And basal-like breast cancers. Breast Cancer Res 2013; 15: R25 [PMID: 23506684]
3. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65 [PMID: 15942193]
4. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139: 871-890 [PMID: 19945376 DOI: 10.1016/j.cell.2009.11.007]
5. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825 [PMID: 19666588 DOI: 10.1007/s10911-010-9173-1]
6. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008; 3: e2888 [PMID: 18682804 DOI: 10.1371/journal.pone.0002888]
7. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715 [PMID: 18485877 DOI: 10.1016/j.cell.2008.03.027]
8. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S, Puisieux A. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet 2012; 8: e1002723 [PMID: 22654675 DOI: 10.1371/journal.pgen.1002723]
9. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-To-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011; 30: 4609-4621 [PMID: 21643013 DOI: 10.1038/onc.2011.184]
10. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008; 68: 10377-10386 [PMID: 19074907 DOI: 10.1158/0008-5472.CAN-08-1444]
11. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101-1108 [PMID: 21822286 DOI: 10.1038/nm.2401]
12. Celià-Terrassa T, Meca-Cortés O, Mateo F, de Paz AM, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, Álvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012; 122: 1849-1868 [PMID: 22505459 DOI: 10.1172/JCI59218]
13. Chui MH. Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step. Int J Cancer 2013; 132: 1487-1495 [PMID: 22833228 DOI: 10.1002/ijc.27745]
14. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-736 [PMID: 23201165 DOI: 10.1016/j.ccr.2012.09.022]
15. Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. Metastatic colonization requires the repression of the epithelialmesenchymal transition inducer Prrx1. Cancer Cell 2012; 22: 709-724 [PMID: 23201163 DOI: 10.1016/j.ccr.2012.10.012]
16. Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 2009; 101: 673-683 [PMID: 19672267 DOI: 10.1038/sj.bjc.6605193]
17. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-2650 [PMID: 19092150 DOI: 10.1056/NEJMoa0803785]
18. Hinkal GW, Grelier G, Puisieux A, Moyret-Lalle C. Complexity in the regulation of Dicer expression: Dicer variant proteins are differentially expressed in epithelial and mesenchymal breast cancer cells and decreased during EMT. Br J Cancer 2011; 104: 387-388 [PMID: 21119658 DOI: 10.1038/sj.bjc.6606022]
19. Courtois-Cox S, Moyret-Lalle C. Epithelial-Mesenchymal Transition and Metastasis: Role of Dicer Expression. Stem Cells and Cancer Stem Cells 2012; 6: 213-229
20. Sawh AN, Duchaine TF. A truncated form of dicer tilts the balance of RNA interference pathways. Cell Rep 2013; 4: 454-463 [PMID: 23933256 DOI: 10.1016/j.celrep.2013.07.013]
21. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111-115 [PMID: 15723655]
22. Valastyan S, Weinberg RA. Metastasis suppression: A role of the Dice(r). Genome Biol 2010; 11: 141 [PMID: 21118581 DOI: 10.1016/j.cell.2011.09.024]
23. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S. A MicroRNA targeting dicer for metastasis control. Cell 2010; 141: 1195-1207 [PMID: 20603000 DOI: 10.1016/j.cell.2010.05.017]
24. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986-990 [PMID: 20962848 DOI: 10.1038/nature09459]
25. Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, Sharp PA. Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell 2012; 21: 848-855 [PMID: 22698408 DOI: 10.1016/j.ccr.2012.04.037]
26. Mudhasani R, Zhu Z, Hutvagner G, Eischen CM, Lyle S, Hall LL, Lawrence JB, Imbalzano AN, Jones SN. Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. J Cell Biol 2008; 181: 1055-1063 [PMID: 18591425 DOI: 10.1083/jcb.200802105]
27. Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005; 579: 5911-5922 [PMID: 16111679]
28. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004 [PMID: 14973191]
29. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261 [PMID: 16461460]
30. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-Tumorous tissues. Oncogene 2006; 25: 2537-2545 [PMID: 16331254]
31. Avril-Sassen S, Goldstein LD, Stingl J, Blenkiron C, Le Quesne J, Spiteri I, Karagavriilidou K, Watson CJ, Tavaré S, Miska EA, Caldas C. Characterisation of microRNA expression in postnatal mouse mammary gland development. BMC Genomics 2009; 10: 548 [PMID: 19930549 DOI: 10.1186/1471-2164-10-548]
32. Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev 2014; 40: 595-604 [PMID: 24286642 DOI: 10.1016/j.ctrv.2013.11.002]
33. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803 [PMID: 17072344]
34. Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP, Croce CM. Estrogen mediated-Activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet 2013; 9: e1003311 [PMID: 23505378 DOI: 10.1371/journal. pgen.1003311]
35. Cai WY, Wei TZ, Luo QC, Wu QW, Liu QF, Yang M, Ye GD, Wu JF, Chen YY, Sun GB, Liu YJ, Zhao WX, Zhang ZM, Li BA. The Wnt-β-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci 2013; 126: 2877-2889 [PMID: 23613467 DOI: 10.1242/jcs.123810]
36. Tahiri A, Leivonen SK, Löders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2014; 35: 76-85 [PMID: 24104550 DOI: 10.1093/carcin/bgt333]
37. DIppolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci 2013; 14: 22202-22220 [PMID: 24284394 DOI: 10.3390/ijms141122202]
38. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, Caldas C. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013; 497: 378-382 [PMID: 23644459 DOI: 10.1038/nature12108]
39. Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, Archer TK. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol 2008; 28: 6426-6438 [PMID: 18710938 DOI: 10.1128/MCB.00359-08]
40. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14: 2115-2124 [PMID: 18755840 DOI: 10.1261/rna.1162708]
41. Harquail J, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy: An overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 2012; 11: 269-280 [PMID: 23248185 DOI: 10.3233/CBM-120291]
42. Adams BD, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-Alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol 2009; 23: 1215-1230 [PMID: 19423651 DOI: 10.1210/me.2009-0062]
43. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010; 42: 1348-1354 [PMID: 20227518 DOI: 10.1016/j.biocel.2010.03.004]
44. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, Sahin O, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70: 9175-9184 [PMID: 20978187 DOI: 10.1158/0008-5472.CAN-10-1318]
45. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005; 7: 1074-1082 [PMID: 16244670]
46. Brandt T, Townsley FM, Teufel DP, Freund SM, Veprintsev DB. Molecular basis for modulation of the p53 target selectivity by KLF4. PLoS One 2012; 7: e48252 [PMID: 23118962 DOI: 10.1371/journal.pone.0048252]
47. Lin CC, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Mol Cell Biol 2011; 31: 2513-2527 [PMID: 21518959 DOI: 10.1128/MCB.01189-10]
48. Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesindependent pathways. Oncogene 2013 Sep 16; Epub ahead of print [PMID: 24037528 DOI: 10.1038/onc.2013.370]
49. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914 [PMID: 18411277 DOI: 10.1074/jbc.C800074200]
50. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589 [PMID: 18483486 DOI: 10.1038/embor.2008.74]
51. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schöler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-Activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495 [PMID: 19935649 DOI: 10.1038/ncb1998]
52. Jang K, Ahn H, Sim J, Han H, Abdul R, Paik SS, Chung MS, Jang SJ. Loss of microRNA-200a expression correlates with tumor progression in breast cancer. Transl Res 2014; 163: 242-251 [PMID: 24280074 DOI: 10.1016/j.trsl.2013.11.005]
53. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-7854 [PMID: 18829540 DOI: 10.1158/0008-5472. CAN-08-1942]
54. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y, Goodall GJ. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22: 1686-1698 [PMID: 21411626 DOI: 10.1091/mbc.E11-02-0103]
55. Pieraccioli M, Imbastari F, Antonov A, Melino G, Raschellà G. Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation. Cell Cycle 2013; 12: 2309-2320 [PMID: 24067373 DOI: 10.4161/cc.25405]
56. Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschellà G. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem 2010; 285: 29434-29445 [PMID: 20622260 DOI: 10.1074/jbc.M109.089045]
57. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601 [PMID: 18376396 DOI: 10.1038/ncb1722]
58. Moes M, Le Béchec A, Crespo I, Laurini C, Halavatyi A, Vetter G, Del Sol A, Friederich E. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One 2012; 7: e35440 [PMID: 22514743 DOI: 10.1371/journal.pone.0035440]
59. Ding X, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem 2013; 288: 10241-10253 [PMID: 23447531 DOI: 10.1074/jbc.M112.443655]
60. Siemens H, Jackstadt R, Hönten S, Kaller M, Menssen A, Götz U, Hermeking H. miR-34 and SNAIL form a doublenegative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-4271 [PMID: 22134354 DOI: 10.4161/cc.10.24.18552]
61. Sass S, Dietmann S, Burk UC, Brabletz S, Lutter D, Kowarsch A, Mayer KF, Brabletz T, Ruepp A, Theis FJ, Wang Y. MicroRNAs coordinately regulate protein complexes. BMC Syst Biol 2011; 5: 136 [PMID: 21867514 DOI: 10.1186/1752-0509-5-136]
62. Subramanyam D, Blelloch R. From microRNAs to targets: pathway discovery in cell fate transitions. Curr Opin Genet Dev 2011; 21: 498-503 [PMID: 21636265 DOI: 10.1016/j.gde.2011.04.011]
63. ODonnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843 [PMID: 15944709]
64. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP. MicroRNA-Antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013; 154: 311-324 [PMID: 23830207 DOI: 10.1016/j.cell.2013.06.026]
65. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011; 147: 382-395 [PMID: 22000016 DOI: 10.1016/j.cell.2011.09.032]
66. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer 2012; 130: 808-816 [PMID: 21387303 DOI: 10.1002/ijc.26037]
67. Charpentier M, Martin S. Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells. Cancers (Basel) 2013; 5: 1545-1565 [PMID: 24240660 DOI: 10.3390/cancers5041545]
68. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 2013; 24: 347-364 [PMID: 24029232 DOI: 10.1016/j.ccr.2013.08.005]
69. Mei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, Jia Z, Pu PY, Kang CS, Yao Z. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 2010; 9: 77-86 [PMID: 20082533]
70. Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP, Xu ZD. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapyinduced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 2011; 18: 16-25 [PMID: 20798686 DOI: 10.1038/cdd.2010.103]
71. Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L, Liu W. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherinmediated PTEN/Akt signaling. Mol Med Rep 2013; 7: 1579-1584 [PMID: 23546450 DOI: 10.3892/mmr.2013.1403]
72. Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y, Dong M, Teng R, Wu L, Fu P, Deng W, Hu W, Teng L. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One 2012; 7: e40008 [PMID: 22808086 DOI: 10.1371/journal.pone.0040008]
73. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159 [PMID: 22351564 DOI: 10.1007/978-1-62703-547-7-14]
74. Lu M, Jolly MK, Levine H, Onuchic JN, Ben-Jacob E. MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. Proc Natl Acad Sci USA 2013; 110: 18144-18149 [PMID: 24154725 DOI: 10.1073/pnas.1318192110]
75. Moreno-Bueno G, Cubillo E, Sarrió D, Peinado H, Rodríguez-Pinilla SM, Villa S, Bolós V, Jordá M, Fabra A, Portillo F, Palacios J, Cano A. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 2006; 66: 9543-9556 [PMID: 17018611]
76. Al Saleh S, Sharaf LH, Luqmani YA. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 2011; 38: 1197-1217 [PMID: 21318221 DOI: 10.3892/ijo.2011.942]
77. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: The PMC42 model as a case study. Cells Tissues Organs 2011; 193: 23-40 [PMID: 21051859 DOI: 10.1159/000320174.PMID: ]
78. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA. FOXC2 expression links epithelialmesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013; 73: 1981-1992 [PMID: 23378344 DOI: 10.1158/0008-5472]
79. Apostolou P, Toloudi M, Chatziioannou M, Ioannou E, Papasotiriou I. Cancer stem cells stemness transcription factors expression correlates with breast cancer disease stage. Curr Stem Cell Res Ther 2012; 7: 415-419 [PMID: 23061814]
80. Huang YH, Luo MH, Ni YB, Tsang JY, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases. Histopathology 2014; 64: 494-503 [PMID: 24382260 DOI: 10.1111/his.12257]
81. Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y. Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 2013; 13: 268 [PMID: 23721519 DOI: 10.1186/1471-2407-13-268]
82. Ravindranath A, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, El-Tanani M. Wnt-β-catenin-Tcf-4 signallingmodulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer 2011; 105: 542-551 [PMID: 21772333 DOI: 10.1038/bjc.2011.269]